Figure S1. Effect of high versus low Hb targets on hypertension in patients with CKD.

S1.1 High Hb versus Low Hb targets (both group treated with ESAs)

| | High Hb | target | Low Hb t | arget | | Risk Ratio | Risk Ratio |
|---|---------|--------|----------|-------|--------|--------------------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% C | M-H, Random, 95% Cl |
| Akizawa 2011 | 17 | 161 | 11 | 160 | 12.4% | 1.54 [0.74, 3.17] | |
| Besarab 1998 | 116 | 618 | 112 | 615 | 28.9% | 1.03 [0.82, 1.30] | + |
| CESG(a substudy)1990 | 2 | 38 | 2 | 40 | 2.6% | 1.05 [0.16, 7.10] | |
| Druke 2006 | 89 | 301 | 59 | 302 | 26.8% | 1.51 [1.14, 2.02] | - |
| Nissenson 1995 | 39 | 78 | 14 | 74 | 17.9% | 2.64 [1.57, 4.45] | |
| Ritz 2007 | 15 | 88 | 9 | 82 | 11.5% | 1.55 [0.72, 3.35] | + |
| Total (95% CI) | | 1284 | | 1273 | 100.0% | 1.49 [1.08, 2.05] | ◆ |
| Total events | 278 | | 207 | | | | |
| Heterogeneity: Tau ² = 0.08; Chi ² = 12.35, df = 5 (P = 0.03); l ² = 60% | | | | | | | 0.01 0.1 1 10 100 |
| Test for overall effect: $Z = 2.45$ (P = 0.01) | | | | | | | 0.010.1110100Favours High Hb targetFavours Low Hb target |

S1.2 ESAs treatment versus no ESAs treatment

| | ESA treatment | | no ESA treatment | | Risk Ratio | | Risk Ratio |
|---|---------------|-------|------------------|-------|------------|---------------------|---|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% C | M-H, Fixed, 95% Cl |
| CESG 1990 | 2 | 38 | 0 | 40 | 0.1% | 5.26 [0.26, 106.06] | · · · · · · · · · · · · · · · · · · · |
| Pfeffer 2009 | 491 | 2012 | 446 | 2026 | 99.0% | 1.11 [0.99, 1.24] | |
| Revicki 1995 | 11 | 43 | 4 | 40 | 0.9% | 2.56 [0.89, 7.39] | |
| Total (95% CI) | | 2093 | | 2106 | 100.0% | 1.13 [1.01, 1.26] | |
| Total events | 504 | | 450 | | | | |
| Heterogeneity: Chi ² = 3.39, df = 2 (P = 0.18); l ² = 41% | | | | | | | |
| Test for overall effect: Z = 2.09 (P = 0.04) | | | | | | | 0.01 0.1 1 10 100 Favours ESA treatment Favours no ESA treatment |

S1.3 Summary of the high Hb versus low Hb group (irrespective of treatment

modality)

| | High Hb target | | Low Hb target | | | Risk Ratio | Risk Ratio |
|---|----------------|-------|---------------|-------|--------|---------------------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% C | M-H, Random, 95% CI |
| Akizawa 2011 | 17 | 161 | 11 | 160 | 7.2% | 1.54 [0.74, 3.17] | + |
| Besarab 1998 | 116 | 618 | 112 | 615 | 22.1% | 1.03 [0.82, 1.30] | + |
| CESG 1990 | 2 | 38 | 0 | 40 | 0.6% | 5.26 [0.26, 106.06] | |
| CESG(a substudy)1990 | 2 | 38 | 2 | 40 | 1.3% | 1.05 [0.16, 7.10] | |
| Druke 2006 | 89 | 301 | 59 | 302 | 19.7% | 1.51 [1.14, 2.02] | - |
| Nissenson 1995 | 39 | 78 | 14 | 74 | 11.4% | 2.64 [1.57, 4.45] | |
| Pfeffer 2009 | 491 | 2012 | 446 | 2026 | 27.2% | 1.11 [0.99, 1.24] | • |
| Revicki 1995 | 11 | 43 | 4 | 40 | 3.9% | 2.56 [0.89, 7.39] | |
| Ritz 2007 | 15 | 88 | 9 | 82 | 6.6% | 1.55 [0.72, 3.35] | + |
| Total (95% CI) | | 3377 | | 3379 | 100.0% | 1.40 [1.11, 1.75] | ◆ |
| Total events | 782 | | 657 | | | | |
| Heterogeneity: Tau ² = 0.0 |)5; Chi² = 18 | | | | | | |
| Test for overall effect: $Z = 2.90$ (P = 0.004) | | | | | | | 0.010.1110100Favours High Hb targetFavours Low Hb target |